Skip to main content
Log in

Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Psoriatic arthritis affects approximately 6–42 % of patients with psoriasis. It is useful for physicians or dermatologists managing psoriasis patients to be aware of how to concurrently manage the joint manifestations, as it is preferable and convenient to use a single agent in such patients. However, only certain therapies are effective for both. Systemic agents, which can be used for both skin and joint manifestations, include methotrexate and ciclosporin. For the group of biologic agents, the tumor necrosis factor inhibitors such as adalimumab, etanercept, infliximab, golimumab and certolizumab are effective. Ustekinumab is a more recently developed agent belonging to the group of anti-IL-12p40 antibodies and has been shown to be efficacious. Newer drugs in the treatment armamentarium that have shown efficacy for both psoriasis and psoriatic arthritis consist of the anti-IL-17 agent, secukinumab, and a phosphodiesterase-4 inhibitor, apremilast. The other anti-IL-17 agents, ixekizumab and brodalumab, as well as the oral Jak inhibitor, tofacitinib, have very limited but promising data. This review paper provides a good overview of the agents that can be used for the concurrent management of skin and joint psoriasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Feletar M, Foley P, Brown MA. Developments in psoriasis and psoriatic arthritis. Drug Discov Today Dis Mech. 2008;5:e47–54.

    Article  Google Scholar 

  2. Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):31–5.

    Article  PubMed  Google Scholar 

  3. Rapp SR, Feldman SR, Exum L, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–7.

    Article  PubMed  CAS  Google Scholar 

  4. Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130:1373–83.

    Article  PubMed  CAS  Google Scholar 

  5. Michalak-Stoma A, Pietrzak A, Szepietowski JC, et al. Cytokine network in psoriasis revisited. Eur Cytokine Netw. 2011;22:160–8.

    PubMed  CAS  Google Scholar 

  6. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339–50.

    Article  PubMed  CAS  Google Scholar 

  7. Raychaudhuri SR. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:183–93.

    Google Scholar 

  8. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52–72.

    Article  CAS  Google Scholar 

  9. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119:3573–85.

    PubMed  CAS  Google Scholar 

  10. Sanchez AP. Immunopathogenesis of psoriasis. An Bras Dermatol. 2010;85:747–9.

    Article  PubMed  Google Scholar 

  11. Costello P, Bresnihan B, O’Farrelly C, et al. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol. 1999;26:1117–24.

    PubMed  CAS  Google Scholar 

  12. Laloux L, Voisin MC, Allain J, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 2001;60:316–21.

    Article  PubMed  CAS  Google Scholar 

  13. Ruderman EM. Evaluation and management of psoriatic arthritis: the role of biologic therapy. J Am Acad Dermatol. 2003;49:S125–32.

    Article  PubMed  Google Scholar 

  14. Fisher VS. Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis. J Manag Care Pharm. 2005;11:33–55.

    PubMed  Google Scholar 

  15. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. Phenotypic and functional features of TH-17 cells in psoriasis and psoriatic arthritis. Arthritis Rheum. 2008;58:S352.

    Google Scholar 

  16. Hebert HL, Ali FR, Bowes J, et al. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol. 2012;166:474–82.

    Article  PubMed  CAS  Google Scholar 

  17. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64:ii37–9.

    Google Scholar 

  18. Gladman DD, Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum. 1995;38:845–50.

    Article  PubMed  CAS  Google Scholar 

  19. Eder L, Chandran V, Pellett F, et al. IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Ann Rheum Dis. 2011;70:1594–8.

    Article  PubMed  CAS  Google Scholar 

  20. Bowes J, Eyre S, Flynn E, et al. Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Ann Rheum Dis. 2011;70:1016–9.

    Article  PubMed  Google Scholar 

  21. Chandran V, Siannis F, Rahman P, et al. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol. 2010;37:1508–12.

    Article  PubMed  CAS  Google Scholar 

  22. Tejasvi T, Stuart P, Nair R, et al. Preliminary pharmacogenetic assessment of tumour necrosis factor (TNF) polymorphisms in psoriasis: response to anti-TNF and systemic therapies [abstract no. FC05]. Br J Dermatol. 2008;159:1391.

    Google Scholar 

  23. Seitz M, Wirthmuller U, Moller B, et al. The -308 tumour necrosis factor-α-gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007;46:93–6.

    Article  CAS  Google Scholar 

  24. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387–94.

    Article  PubMed  CAS  Google Scholar 

  25. Gladman DD. Traditional and newer therapeutic options for psoriatic arthritis. Drugs. 2005;65:1223–38.

    Article  PubMed  CAS  Google Scholar 

  26. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.

    Article  PubMed  Google Scholar 

  27. Gladman DD. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012;38:373–86.

    Article  PubMed  Google Scholar 

  28. Scarpa R, Atteno M, Costa L, et al. Early psoriatic arthritis. J Rheumatol Suppl. 2009;83:26–7.

    Article  PubMed  Google Scholar 

  29. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.

    Article  PubMed  Google Scholar 

  30. Yamauchi PS, Rizk D, Kormeili T, et al. Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol. 2003;49:S66–77.

    Article  PubMed  Google Scholar 

  31. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005;53:652–9.

    Article  PubMed  Google Scholar 

  32. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349:658–65.

    Article  PubMed  CAS  Google Scholar 

  33. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol. 2006;54:1013–8.

    Article  PubMed  Google Scholar 

  34. Scarpa R, Peluso R, Atteno M, et al. The effectiveness of a traditional therapeutic approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. 2008;27:823–6.

    Article  PubMed  Google Scholar 

  35. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51:1368–77.

    Article  CAS  Google Scholar 

  36. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859–64.

    Article  PubMed  CAS  Google Scholar 

  37. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–40.

    Article  PubMed  CAS  Google Scholar 

  38. Daly M, Alikhan A, Armstrong AW. Combination systemic therapies in psoriatic arthritis. J Dermatol Treat. 2011;22:276–84.

    Article  CAS  Google Scholar 

  39. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23:5–70.

    Article  Google Scholar 

  40. Stern RS. Lymphoma risk in psoriasis. Arch Dermatol. 2006;142:1132–5.

    Article  PubMed  Google Scholar 

  41. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol. 2001;16:1395–401.

    Article  PubMed  CAS  Google Scholar 

  42. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111–8.

    Article  PubMed  CAS  Google Scholar 

  43. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–85.

    Article  PubMed  CAS  Google Scholar 

  44. Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90:711–6.

    Google Scholar 

  45. Kalb Re, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation consensus conference. J Am Acad Dermatol. 2009;60:824–37.

  46. Erickson AR, Reddy V, Vogelgesang SA, et al. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum. 1995;38:1115–9.

    Article  PubMed  CAS  Google Scholar 

  47. Thomas JA, Aithal GP. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Am J Clin Dermatol. 2005;6:357–63.

    Article  PubMed  Google Scholar 

  48. MacDonald A, Burden AD. Noninvasive monitoring for methotrexate hepatotoxicity. Br J Dermatol. 2005;152:405–8.

    Article  PubMed  CAS  Google Scholar 

  49. Chalmers RJG, Kirby B, Smith A, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol. 2005;152:444–50.

    Article  PubMed  CAS  Google Scholar 

  50. Bray AP, Barnova I, Przemioslo R, et al. Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy. Br J Dermatol. 2012;166:1125–7.

    Article  PubMed  CAS  Google Scholar 

  51. Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol. 2012;18:163–73.

    Article  PubMed  Google Scholar 

  52. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134:960–74.

    Article  PubMed  Google Scholar 

  53. Berth-Jones J, Henderson CA, Munro CS, et al. Treatment of psoriasis with intermittent short course cyclosporine (Neoral): a multicenter study. Br J Dermatol. 1997;136:527–30.

    Article  PubMed  CAS  Google Scholar 

  54. Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporine (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicenter, randomized study; the PISCES study group. Br J Dermatol. 1999;141:283–91.

    Article  PubMed  CAS  Google Scholar 

  55. Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis: results of a meta-analysis in 579 patients. Am J Clin Dermatol. 2001;2:41–7.

    Article  PubMed  CAS  Google Scholar 

  56. Mrowietz U, Farber L, Henneicke-von Zepelin HH, et al. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study; German multicenter study. J Am Acad Dermatol. 1995;33:470–5.

    Google Scholar 

  57. Shupack J, Abel E, Bauer E, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol. 1997;36:423–32.

    Article  PubMed  CAS  Google Scholar 

  58. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, multi-blind trial. N Engl J Med. 1991;324:277–84.

    Article  PubMed  CAS  Google Scholar 

  59. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120:211–6.

    Article  PubMed  CAS  Google Scholar 

  60. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358:1042–5.

    Article  PubMed  CAS  Google Scholar 

  61. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59:841–9.

    Article  PubMed  CAS  Google Scholar 

  62. Liang GC, Barr WG. Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol. 2001;7:366–70.

    Article  PubMed  CAS  Google Scholar 

  63. Reich K, Hummel KM, Beckman I, et al. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol. 2002;146:335–6.

    Article  PubMed  CAS  Google Scholar 

  64. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum. 2004;50:1939–50.

    Article  PubMed  CAS  Google Scholar 

  65. Nash P, Thaci D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology. 2006;212:238–49.

    Article  PubMed  CAS  Google Scholar 

  66. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs. 1999;58:1137–64.

    Article  PubMed  CAS  Google Scholar 

  67. Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66:1393–7.

    Article  PubMed  CAS  Google Scholar 

  68. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.

    Article  PubMed  Google Scholar 

  69. Menter A, Tyring S, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15.

    Article  PubMed  Google Scholar 

  70. Mease P, Gladman D, Ritchlin C, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum. 2005;52:3279–89.

    Article  PubMed  CAS  Google Scholar 

  71. Gladman D, Mease P, Ritchlin C, et al. Adalimumab for long-term treatment of psoriatic arthritis. Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trials. Arthritis Rheum. 2007;56:476–88.

    Article  PubMed  CAS  Google Scholar 

  72. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–64.

    Article  PubMed  Google Scholar 

  73. Philipp S, Wilsmann-Theis D, Weyergraf A, et al. Combination of adalimumab with traditional systemic antipsoriatic drugs—a report of 39 cases. J Dtsch Dermatol Ges. 2012;10:821–37.

    PubMed  Google Scholar 

  74. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153:1192–9.

    Article  PubMed  CAS  Google Scholar 

  75. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598–603.

    Article  PubMed  Google Scholar 

  76. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–22.

    Article  PubMed  CAS  Google Scholar 

  77. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–72.

    Article  PubMed  CAS  Google Scholar 

  78. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.

    Article  PubMed  Google Scholar 

  79. Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167:649–57.

    Article  PubMed  CAS  Google Scholar 

  80. Driessen RJ, van de Kerkhof PC, de Jong EM. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol. 2008;159:460–3.

    Article  PubMed  CAS  Google Scholar 

  81. Zacharie C, Mork NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88:495–501.

    Article  CAS  Google Scholar 

  82. Heiberg MS, Kaufmann C, Rodevand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis. 2007;66:1038–42.

    Article  PubMed  CAS  Google Scholar 

  83. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234–40.

    Google Scholar 

  84. Kristensen LE, Gulfe A, Saxne T, et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis. 2008;67:364–9.

    Article  PubMed  CAS  Google Scholar 

  85. Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford). 2002;41:329–37.

    Article  CAS  Google Scholar 

  86. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet. 2001;357:1842–7.

    Article  PubMed  CAS  Google Scholar 

  87. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534–42.

    Article  PubMed  Google Scholar 

  88. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–74.

    Article  PubMed  CAS  Google Scholar 

  89. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227–36.

    Article  PubMed  CAS  Google Scholar 

  90. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–7.

    Article  PubMed  CAS  Google Scholar 

  91. Vermeire S, Norman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56:1226–31.

    Article  PubMed  CAS  Google Scholar 

  92. Lecluse LL, Piskin G, Mekkes JR, et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008;159:527–36.

    Article  PubMed  CAS  Google Scholar 

  93. Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naïve patients: the RESPOND study. Ann Rheum Dis. 2012;71:541–8.

    Article  PubMed  CAS  Google Scholar 

  94. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1–15.

    Google Scholar 

  95. Xu Z, Vu P, Lee H, et al. Population pharmacokinetics of golimumab an anti-tumor necrosis factor-α human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009;49:1056–70.

    Article  PubMed  CAS  Google Scholar 

  96. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–86.

    Article  PubMed  CAS  Google Scholar 

  97. Kavanaugh A, van der Heijde D, McInnes I, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III randomized, placebo-controlled trial. Arthritis Rheum. 2012;64:2504–17.

    Article  PubMed  CAS  Google Scholar 

  98. National Institute for Health and Clinical Excellence. Golimumab for the treatment of psoriatic arthritis. London, UK: National Institute for Health and Clinical Excellence, April 2011. NICE technology appraisal guidance no: 220.

  99. Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167:180–90.

    Article  PubMed  CAS  Google Scholar 

  100. Mease PJ, Fleischmann R, Deodhar A, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (RAPID-PSA) [abstract no. LB0001]. The European League against Rheumatism; 2012 June 6–9, Berlin.

  101. Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther. 2009;22:56–60.

    Article  PubMed  Google Scholar 

  102. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results form a randomized, double blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–74.

    Article  PubMed  CAS  Google Scholar 

  103. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010;162:137–46.

    Article  PubMed  CAS  Google Scholar 

  104. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12.23 monoclonal antibody, in patients with psoriasis: 52-week results form a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–84.

    Article  PubMed  CAS  Google Scholar 

  105. Griffiths CEM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–28.

    Article  PubMed  CAS  Google Scholar 

  106. Gaffen SL, Kramer JM, Yu JJ, et al. The IL-17 cytokine family. Vitam Horm. 2006;74:255–82.

    Article  PubMed  CAS  Google Scholar 

  107. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717–24.

    Article  PubMed  CAS  Google Scholar 

  108. Korn T, Betelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517.

    Article  PubMed  CAS  Google Scholar 

  109. Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation [published erratum appears in Immunity 2011;35:649]. Immunity. 2011;35:596–610.

    Article  PubMed  CAS  Google Scholar 

  110. van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182:5836–45.

    Article  PubMed  CAS  Google Scholar 

  111. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–9.

    Article  PubMed  CAS  Google Scholar 

  112. McInnes I, Sieper J, Braun J, et al. Anti-interleukin 17A monoclonal antibody secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2011;63(Suppl 10):779.

    Google Scholar 

  113. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583–90.

    Article  PubMed  CAS  Google Scholar 

  114. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10:1503–9.

    Article  PubMed  CAS  Google Scholar 

  115. Claveau D, Chen SL, O’Keefe S, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2004;310:752–60.

    Article  PubMed  CAS  Google Scholar 

  116. Eigler A, Siegmund B, Emmerich U, et al. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol. 1998;63:101–7.

    PubMed  CAS  Google Scholar 

  117. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273–87.

    Article  PubMed  CAS  Google Scholar 

  118. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b, randomized, placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668–77.

    Article  PubMed  CAS  Google Scholar 

  119. Gudjonsson JE, Johnston A, Ellis CN. Novel systemic drugs under investigation for the treatment of psoriasis. J Am Acad Dermatol. 2012;67:139–47.

    Article  PubMed  CAS  Google Scholar 

  120. Schafer P, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842–55.

    Article  PubMed  CAS  Google Scholar 

  121. Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24:1529–38.

    Article  PubMed  CAS  Google Scholar 

  122. Papp K, Zeldis J, Rohane P, et al. A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis [abstract no. P2614]. J Am Acad Dermatol. 2008;58:AB3(2 Suppl 2).

  123. Papp K, Hu A, Day R. Oral apremilast is active in the treatment of moderate to severe plaque psoriasis: results from a phase 2b, randomized, controlled study (PSOR-005) [abstract no. 273]. J Invest Dermatol. 2011;131.

  124. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156–67.

    Article  PubMed  CAS  Google Scholar 

  125. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;11:7–41.

    Google Scholar 

  126. Fox DA. Kinase inhibition—a new approach to the treatment of rheumatoid arthritis. N Engl J Med. 2012;367:565–7.

    Article  PubMed  CAS  Google Scholar 

  127. Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacological effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009;129:2299–302.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

There was no funding provided for preparation and writing of this paper. None of the authors have any conflicts of interest to declare.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emily Yiping Gan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gan, E.Y., Chong, WS. & Tey, H.L. Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents. BioDrugs 27, 359–373 (2013). https://doi.org/10.1007/s40259-013-0025-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-013-0025-6

Keywords

Navigation